YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection

被引：0
|
作者：
Schiavon, L. L. [1 ]
Narciso-Schiavon, J. L. [1 ]
Carvalho-Filho, R. J. [1 ]
Lanzoni, V. P. [2 ]
Silva, A. E. B. [1 ]
Ferraz, M. L. G. [1 ]
机构：
[1] Univ Fed Sao Paulo, Dept Gastroenterol, Hepatitis Div, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Pathol, Sao Paulo, Brazil
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
755
引用
收藏
页码：S281 / S282
页数：2
相关论文
共 50 条
  • [21] Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease
    Tran, A
    Benzaken, S
    Saint-Paul, MC
    Guzman-Granier, E
    Hastier, P
    Pradier, C
    Barjoan, EM
    Demuth, N
    Longo, F
    Rampal, P
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2000, 12 (09) : 989 - 993
  • [22] Serum YKL-40 and PIIINP levels as prognostic markers in patients with alcoholic liver diseases.
    Noejgaard, C
    Becker, U
    Johansen, J
    Christensen, E
    Price, PA
    Skovgaard, LT
    HEPATOLOGY, 2002, 36 (04) : 399A - 399A
  • [23] Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B
    Lebensztejn, D. M.
    Skiba, E.
    Werpachowska, I
    Sobaniec-Lotowska, M. E.
    Kaczmarski, M.
    ADVANCES IN MEDICAL SCIENCES, 2007, 52 : 120 - 124
  • [24] Predictors of Liver Fibrosis in Patients with Chronic HCV Infection
    Ceylan, Bahadir
    Yardimci, Cem
    Fincanci, Muzaffer
    Tozalgan, Umit
    Eren, Gulhan
    Muderrisoglu, Cuneyt
    Inci, Ayse
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2012, 32 (06): : 1522 - 1529
  • [25] Serum hyaluronic acid (HA) in dialysis patients: Relationship to chronic hepatitis C viral (HCV) infection.
    deMedina, M
    Ashby, M
    Hill, M
    Perez, GO
    Pennell, JP
    Schiff, ER
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A1071 - A1071
  • [26] Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease.
    Tran, A
    Benzaken, S
    Marine-Barjoan, E
    Hastier, P
    Saint-Paul, MC
    Christian, P
    Demuth, N
    Rampal, P
    HEPATOLOGY, 2000, 32 (04) : 191A - 191A
  • [27] Comparison between galectin-3 and YKL-40 levels for the assessment of liver fibrosis in cirrhotic patients
    Del Turco, Serena
    De Simone, Paolo
    Ghinolfi, Davide
    Gaggini, Melania
    Basta, Giuseppina
    ARAB JOURNAL OF GASTROENTEROLOGY, 2021, 22 (03) : 187 - 192
  • [28] Serum YKL-40 as a marker of liver fibrosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
    Mano, Yohei
    Kumagai, Erina
    Shoji, Hirotaka
    Yoshio, Sachiyo
    Sugiyama, Masaya
    Korenaga, Masaaki
    Arai, Taeang
    Itokawa, Norio
    Atsukawa, Masanori
    Hyogo, Hideyuki
    Chayama, Kazuaki
    Ohashi, Tomohiko
    Ito, Kiyoaki
    Yoneda, Masashi
    Kawaguchi, Takumi
    Torimura, Takuji
    Nozaki, Yuichi
    Mizokami, Masashi
    Kanto, Tatsuya
    HEPATOLOGY, 2016, 64 : 799A - 799A
  • [29] Liver steatosis is not associated with fibrosis in patients with chronic HCV infection
    Asselah, T
    Boyer, N
    Guimont, MC
    Cazals, D
    Tubach, F
    Nahon, K
    Vidaud, D
    Martinot, M
    Vidaud, M
    Degott, C
    Valla, D
    Marcellin, P
    JOURNAL OF HEPATOLOGY, 2003, 38 : 124 - 125
  • [30] Prediction of significant liver fibrosis in kidney transplant patients with chronic hepatitis C virus (HCV) infection: The TX-3 index
    Schiavon, L. L.
    Carvalho-Filho, R. J.
    Narciso-Schiavon, J. L.
    Barbosa, D. V.
    Lanzoni, V. P.
    Ferraz, M. L. G.
    Silva, A. E. B.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S281 - S281
12345